



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Vital Limited
1/08/2025
21/02/2025

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

James Sclater
Vital Limited
n/a
Director

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

Ordinary shares	Ordinary shares
Legal and beneficial ownership	Legal and beneficial ownership

For that relevant interest-

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

106,666	1,500
0	0
Lynda Maree Sclater and Paul John McCormick as trustees of the Hauraki Trust	James Matheson Sclater and Paul John McCormick as trustees of the Kailua Trust
Tait International Limited	Tait International Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

N/A
N/A

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

N/A
N/A
N/A
N/A
N/A
N/A

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A
N/A

Details of transactions giving rise to acquisition or disposal


Total number of transactions to which notice relates:

1

Details of transactions requiring disclosure-

Date of transaction:

31-Jul-25	31-Jul-25
-----------	-----------

	On 19 June 2025, Tait International Limited made a full takeover offer under the Takeovers Code for all of the equity securities in Vital Limited. On 31 July 2025, the Trust accepted the offer in respect of all of their ordinary shares in Vital Limited, being 106,666 ordinary shares. Those shares will only be sold to Tait International Limited if the offer becomes unconditional in all respects. If the offer does not become unconditional, it will lapse and the Trust will retain legal and beneficial ownership of their shares.	On 19 June 2025, Tait International Limited made a full takeover offer under the Takeovers Code for all of the equity securities in Vital Limited. On 31 July 2025, the Trust accepted the offer in respect of all of their ordinary shares in Vital Limited, being 1,500 ordinary shares. Those shares will only be sold to Tait International Limited if the offer becomes unconditional in all respects. If the offer does not become unconditional, it will lapse and the Trust will retain legal and beneficial ownership of their shares.
Nature of transaction:	Tait International Limited	Tait International Limited
Name of any other party or parties to the transaction (if known):	\$0.45 per share, being \$47,999.70 in aggregate. This payment will only be made if Tait International Limited's offer becomes unconditional.	\$0.45 per share, being \$675 in aggregate. This payment will only be made if Tait International Limited's offer becomes unconditional.
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	106,666	1,500
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>		
Whether relevant interests were acquired or disposed of during a closed period:	N/A	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A	
Date of the prior written clearance (if any):	N/A	
Summary of other relevant interests after acquisition or disposal:		
Class of quoted financial products:	N/A	
Nature of relevant interest:	N/A	
<i>For that relevant interest,-</i>		
Number held in class:	N/A	
Current registered holder(s):	N/A	
<i>For a derivative relevant interest,-</i>		
Type of derivative:	N/A	
Details of derivative,-		
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A	
A statement as to whether the derivative is cash settled or physically settled:	N/A	
Maturity date of the derivative (if any):	N/A	
Expiry date of the derivative (if any):	N/A	
The price's specified terms (if any):	N/A	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A	
<i>For that derivative relevant interest,-</i>		
Parties to the derivative:	N/A	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A	
Certification		
I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.		
Signature of director or officer:		
Date of signature:	1-Aug-25	